Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The B-cell tumor promoter Bcl-3 suppresses inflammation-associated colon tumorigenesis in epithelial cells

Abstract

Bcl-3 is an atypical member of the inhibitor of kappa light polypeptide gene enhancer in B-cells (IκB) family. It associates with p50/nuclear factor-κB1 (NF-κB1) and p52/NF-κB2 homodimers in nuclei where it modulates transcription in a context-dependent manner. A subset of B-cell tumors exhibits recurrent translocations of Bcl-3, resulting in overexpression. Elevated expression without translocations is also observed in various B-cell lymphomas and even some solid tumors. Here we investigated the role of Bcl-3 in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors, a mouse model for colitis-associated colorectal cancers in humans. Contrary to expectations, Bcl-3 suppressed colorectal tumor formation: Bcl-3-deficient mice were relatively protected from DSS-induced epithelial damage and developed more polyps after AOM/DSS treatment, although polyp size was unaffected. DSS-challenged mutant mice exhibited increased recruitment of myeloid-derived suppressor cells, consistent with protection of the epithelium. Loss of Bcl-3 in intestinal epithelial cells was sufficient to increase tumorigenesis. The added tumor burden in mutant mice was dependent on tumor necrosis factor-α (TNFα), a tumorigenic, NF-κB-mediated signaling pathway that was dampened by Bcl-3. These findings reveal a tumor-suppressive role for Bcl-3 in this inflammation-associated cancer model. Bcl-3 thus functions as a tumor promoter or suppressor, depending on the cellular and environmental context.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Hayden MS, Ghosh S . NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203–234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Siebenlist U, Brown K, Claudio E . Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 2005; 5: 435–445.

    Article  CAS  PubMed  Google Scholar 

  3. Hinz M, Arslan SC, Scheidereit C . It takes two to tango: IkappaBs, the multifunctional partners of NF-kappaB. Immunol Rev 2012; 246: 59–76.

    Article  PubMed  Google Scholar 

  4. Palmer S, Chen YH . Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription. Immunol Res 2008; 42: 210–218.

    Article  CAS  PubMed  Google Scholar 

  5. Schuster M, Annemann M, Plaza-Sirvent C, Schmitz I . Atypical IkappaB proteins - nuclear modulators of NF-kappaB signaling. Cell Commun Signal 2013; 11: 23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Maldonado V, Melendez-Zajgla J . Role of Bcl-3 in solid tumors. Mol Cancer 2011; 10: 152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kashatus D, Cogswell P, Baldwin AS . Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006; 20: 225–235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R . Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665–677.

    Article  CAS  PubMed  Google Scholar 

  9. Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y et al. The IkappaB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol 2013; 5: 280–282.

    Article  CAS  PubMed  Google Scholar 

  10. Wakefield A, Soukupova J, Montagne A, Ranger J, French R, Muller WJ et al. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors. Cancer Res 2013; 73: 745–755.

    Article  CAS  PubMed  Google Scholar 

  11. Grivennikov SI . Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013; 35: 229–244.

    Article  CAS  PubMed  Google Scholar 

  12. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog 2011; 10: 9.

    Article  CAS  PubMed  Google Scholar 

  13. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560–570.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828–831.

    Article  CAS  PubMed  Google Scholar 

  15. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285–296.

    Article  CAS  PubMed  Google Scholar 

  16. Burkitt MD, Hanedi AF, Duckworth CA, Williams JM, Tang JM, O'Reilly LA et al. NF-kappaB1, NF-kappaB2 and c-Rel differentially regulate susceptibility to colitis-associated adenoma development in C57BL/6 mice. J Pathol 2015; 236: 326–336.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Tassi I, Rikhi N, Claudio E, Wang H, Tang W, Ha HL et al. The NF-kappaB regulator Bcl-3 modulates inflammation during contact hypersensitivity reactions in radioresistant cells. Eur J Immunol 2015; 45: 1059–1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tang W, Wang H, Claudio E, Tassi I, Ha HL, Saret S et al. The oncoprotein and transcriptional regulator Bcl-3 governs plasticity and pathogenicity of autoimmune T cells. Immunity 2014; 41: 555–566.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. O'Carroll C, Moloney G, Hurley G, Melgar S, Brint E, Nally K et al. Bcl-3 deficiency protects against dextran-sodium sulphate-induced colitis in the mouse. Clin Exp Immunol 2013; 173: 332–342.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nielsen OH . New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) 2014; 1: 3.

    Google Scholar 

  22. Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y et al. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G850–G859.

    Article  CAS  PubMed  Google Scholar 

  23. Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, Yamaguchi T et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 2003; 18: 560–569.

    Article  CAS  PubMed  Google Scholar 

  24. Pene F, Paun A, Sonder SU, Rikhi N, Wang H, Claudio E et al. The IkappaB family member Bcl-3 coordinates the pulmonary defense against Klebsiella pneumoniae infection. J Immunol 2011; 186: 2412–2421.

    Article  CAS  PubMed  Google Scholar 

  25. Tassi I, Claudio E, Wang H, Tang W, Ha HL, Saret S et al. The NF-kappaB regulator Bcl-3 governs dendritic cell antigen presentation functions in adaptive immunity. J Immunol 2014; 193: 4303–4311.

    Article  CAS  PubMed  Google Scholar 

  26. Diaz-Montero CM, Finke J, Montero AJ . Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 2014; 41: 174–184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Manjili MH, Wang XY, Abrams S . Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs. Front Immunol 2014; 5: 303.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN . CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013; 24: 631–644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pasparakis M . Role of NF-kappaB in epithelial biology. Immunol Rev 2012; 246: 346–358.

    Article  PubMed  Google Scholar 

  30. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91–102.

    Article  CAS  PubMed  Google Scholar 

  31. Franzoso G, Carlson L, Scharton-Kersten T, Shores EW, Epstein S, Grinberg A et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 1997; 6: 479–490.

    Article  CAS  PubMed  Google Scholar 

  32. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998; 187: 147–159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD . The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32: 379–391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Eigenbrod T, Bode KA, Dalpke AH . Early inhibition of IL-1beta expression by IFN-gamma is mediated by impaired binding of NF-kappaB to the IL-1beta promoter but is independent of nitric oxide. J Immunol 2013; 190: 6533–6541.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We greatly appreciate the constructive inputs provided by all members of the Siebenlist laboratory. This research was supported by the Intramural Research Program of NIAID, NIH.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to U Siebenlist.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, W., Wang, H., Ha, H. et al. The B-cell tumor promoter Bcl-3 suppresses inflammation-associated colon tumorigenesis in epithelial cells. Oncogene 35, 6203–6211 (2016). https://doi.org/10.1038/onc.2016.152

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2016.152

This article is cited by

Search

Quick links